Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Bought by Sterling Capital Management LLC

Sterling Capital Management LLC lifted its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 56.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 25,212 shares of the company’s stock after purchasing an additional 9,060 shares during the period. Sterling Capital Management LLC’s holdings in Roivant Sciences were worth $298,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Russell Investments Group Ltd. lifted its holdings in Roivant Sciences by 478.6% in the 4th quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company’s stock worth $28,000 after buying an additional 1,948 shares in the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in shares of Roivant Sciences during the fourth quarter worth about $39,000. GAMMA Investing LLC lifted its stake in shares of Roivant Sciences by 57.0% in the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock worth $42,000 after acquiring an additional 1,288 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in Roivant Sciences by 27.0% during the 4th quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company’s stock valued at $84,000 after purchasing an additional 1,507 shares in the last quarter. Finally, Wells Fargo & Company MN grew its position in shares of Roivant Sciences by 84.1% during the fourth quarter. Wells Fargo & Company MN now owns 7,501 shares of the company’s stock worth $89,000 after buying an additional 3,426 shares in the last quarter. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Roivant Sciences

In other Roivant Sciences news, COO Eric Venker sold 434,478 shares of the firm’s stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $10.82, for a total value of $4,701,051.96. Following the sale, the chief operating officer now owns 1,127,290 shares in the company, valued at approximately $12,197,277.80. This trade represents a 27.82 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Rakhi Kumar sold 227,500 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $10.43, for a total value of $2,372,825.00. Following the transaction, the chief accounting officer now owns 163,264 shares of the company’s stock, valued at approximately $1,702,843.52. This represents a 58.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,395,541 shares of company stock worth $15,028,538. Insiders own 7.90% of the company’s stock.

Roivant Sciences Stock Performance

Shares of NASDAQ:ROIV opened at $10.15 on Monday. The company’s fifty day moving average is $10.33 and its two-hundred day moving average is $11.17. Roivant Sciences Ltd. has a 1-year low of $8.73 and a 1-year high of $13.06. The stock has a market capitalization of $7.24 billion, a price-to-earnings ratio of -67.66 and a beta of 1.25.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. Sell-side analysts expect that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have commented on ROIV. HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a research note on Tuesday, February 11th. Cantor Fitzgerald raised shares of Roivant Sciences to a “strong-buy” rating in a research report on Tuesday, March 4th.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.